Identification of Animal Models and Cell-based Models
for Improved Understanding of Human Disease and Drug Screening
on the International Space Station U.S. National Laboratory
RFI No. CASIS 2015-1 | Due Date: November 14, 2014
The ISS National Lab is pleased to release this Request For Information (RFI) to identify and gather information from subject matter experts and entities with experience in human disease research, disease modeling, and translational medicine that may be applied to accelerate research in disease pathophysiology, target identification, and the in vivo evaluation of novel therapeutic agents and treatments using animal models and/or cell-based models in microgravity. Based on expertise available, the ISS National Lab may issue a Request for Proposals that will provide funding for flight research on the ISS National Lab seeking to use animal or cell-based models in microgravity for human disease modeling.
Please follow the steps below to indicate your interest in this project:
|Download the PDF to review the ISS National Lab’s Request for Information:
|Please click the following link to find instructions to submit a White Paper in response to RFI No. CASIS 2015-1:
|Proposals submission period concluded at 5:00pm EST on November 14, 2014.
All submitted RFIs are undergoing a review process. Please continue to follow our site for updates and results announcements.
|For relevant information regarding past research and available flight hardware/facilities for support of disease models research on the International Space Station, visit the following links:
NASA Bioscience Database
** Please verify that none of the information submitted is subject to the export control laws of the United States, such as the EAR or the ITAR; if any information is subject to such laws, please mark all pages containing such information and identify the appropriate export control jurisdiction and classification. **
Michael Roberts, ISS National Lab Sr. Research Pathway Manager
Office phone: (321) 757-6127(321) 757-6127
Email: [email protected]